Herbalife (HLF) Tops Q1 EPS by 27c, Raises FY EPS Guidance

Go back to Herbalife (HLF) Tops Q1 EPS by 27c, Raises FY EPS Guidance

Shorting Herbalife (HLF) is 'Absurdly Risky', Says Pivotal Research

May 6, 2016 8:05 AM EDT

Pivotal Research maintained a Buy rating on Herbalife (NYSE: HLF) with a price target of $90. Comments follow the release of strong Q1 results and an updated FTC disclosure. Analyst Timothy Ramey thinks the end game is near on the FTC matter, and he said being short Herbalife at this time is "absurdly risky."

Yesterday the company said in an SEC filing:

The outcome of these matters with the FTC, whether by mutual resolution or through litigation, could have a material adverse impact on the Companys business operations, its results of... More

UPDATE: Herbalife (HLF) Says Talks With FTC Have Progressed to Advanced Stage

May 5, 2016 4:37 PM EDT

(Updated - May 5, 2016 5:28 PM EDT)

(Updated)

Herbalife (NYSE: HLF) said talks with the FTC have progressed to an advanced stage, according to Bloomberg, citing an email statement.

"While there are a number of open issues, those discussions have progressed to an advanced stage and the range of outcomes now includes litigation or settlement. If a settlement is reached with the FTC, it would likely include injunctive and other relief as well as a monetary payment with our best estimate of a payment being $200 million," the company told... More